CONMED Corporation CNMD is well poised for growth in the coming quarters, courtesy of its broad product spectrum. The optimism, led by the solid first-quarter 2024 performance and a potential General Surgery, is expected to contribute further. However, headwinds from supply-chain constraints and data security threats persist. This Zacks Rank #3 (Hold) company’s shares have lost 38.4% year to date against the industry’s 1.5% growth. The S&P 500 Index has increased 15.1% in the same time frame. CONMED, the renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $2.06 billion. The company projects 24.4% growth over the next five years and expects to maintain its strong performance going forward. Its earnings surpassed estimates in three of the trailing four quarters and missed the same once, delivering an average surprise of 3.94%. Zacks Investment Research Image Source: Zacks Investment Research Let’s delve deeper. Potential in General Surgery: The segment consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products, as well as electrosurgical generators and related instruments. CONMED’s unique products and solutions within the General Surgery segment have been providing a competitive edge in the MedTech space. One of these products, the Anchor Tissue Retrieval bag, deserves a special mention. It is one of the major platforms in the company’s specimen bag portfolio. Broad Product Spectrum: CONMED offers a broad line of surgical products, including several new devices in the Orthopedic, Laparoscopic, Robotic, Open Surgery, Gastroenterology, Pulmonary and Cardiology sections. Products like the Hi-Fi Tape and the Hi-Fi suture interface are critical components of repair security in the rotator cuff repair space. During the fourth quarter, CNMD remained focused on the introduction of a delivery system for MIS rotator cuff repair. Other notable offerings were the MicroFree platform in Orthopedics, the TruShot, the Y-Knot Pro and the CRYSTALVIEW Pump. The Anchor Tissue Retrieval bag is a unique product under the General Surgery arm. Solid Recurring Revenue Base: Approximately 80% of CONMED’s revenues are recurring, derived from the sale of disposable single-use products. The remaining 20% comes from the sale of capital equipment (such as powered drills and saws for surgery, electrosurgical generators, video-imaging cameras, fluid control systems and surgical hand-pieces). This, in turn, creates demand for complementary single-use items. Hospitals and clinics are expanding the use of single-use, disposable products. This endeavor is aimed at reducing expenses related to sterilizing surgical instruments and products following surgery. CONMED’s revenues totaled $312.3 million in the first quarter of 2024, up 5.7% year over year. Downsides Regulatory Requirements: Substantially, all CONMED products are classified as class II medical devices, subject to regulations from numerous agencies and legislative bodies worldwide. As a manufacturer of medical devices, the company’s manufacturing processes and facilities are subject to on-site inspection and constant review by the FDA for compliance with the Quality System Regulations. Supply Constraints: Although CONMED recorded strong growth across all segments in the fourth quarter, the legacy orthopedic business was hurt by supply-chain constraints. The supply disruption continued to pose a headwind for the company during the first quarter of 2024. CNMD expects supply-chain issues to improve going forward in 2024. Moreover, revenues were hurt 0.2% by unfavorable currency movement during the first quarter. Estimate Trend CONMED is witnessing a stable estimate revision trend for 2024. In the past 30 days, the Zacks Consensus Estimate for earnings remained unchanged at $4.30 per share. The same for the company’s second-quarter revenues is pegged at $334.6 million, indicating a 5.3% improvement from the year-ago quarter’s reported number. The bottom-line estimate for the second quarter is expected to improve 10.8% from the year-ago period’s level of 83 cents. CONMED Corporation Price CONMED Corporation Price CONMED Corporation price | CONMED Corporation Quote Stocks to Consider Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, ResMed RMD and Hologic HOLX. DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have risen 36.4% compared with the industry’s 9.3% growth year to date. ResMed, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 13.2% in 2024. Its earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 2.81%. RMD’s shares have risen 6.9% year to date compared with the industry’s 2.8% growth. Hologic, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 7.4%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.94%. Hologic’s shares have risen 0.3% year to date compared with the industry’s 4.7% growth. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report ResMed Inc. (RMD):Free Stock Analysis Report Hologic, Inc. (HOLX):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Here's Why You Should Retain CONMED (CNMD) Stock for Now
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...